While many microfluidic platforms use nanowell- or nanopen-based systems, assays on Lightcast’s Envisia platform are carried out within a droplet environment.
A droplet-based system has some key advantages for antibody discovery, including:
- Quicker and more accurate identification of positive hits
- Deeper, more specific insights into cellular function
- The ability to ensure that mRNA from ALL positive hits — including from dying cells — can be dispensed and sequenced
Watch the video to hear Lightcast's Field Application Team Leader Jonathan Didier explain these benefits in more detail.
